Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 5/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 6/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745614 | 0.88 | PTPN11 (0.47) | PTPN11BRD4HTR6AURKAPDPK1 | |
| SCHEMBL13745570 | 0.85 | PTPN11 (0.44) | PTPN11BRD4CDK8HTR6AURKA | |
| SCHEMBL13745784 | 0.85 | PTPN11 (0.45) | PTPN11BRD4HTR6AURKAPDPK1 | |
| SCHEMBL13745675 | 0.85 | PTPN11 (0.45) | PTPN11BRD4HTR6AURKAPDPK1 | |
| SCHEMBL13746014 | 0.84 | PTPN11 (0.45) | PTPN11BRD4CDK8HTR6PDPK1 | |
| SCHEMBL13746279 | 0.84 | MAPK8 (0.53) | PTPN11BRD4HTR6AURKAPDPK1 | |
| SCHEMBL13746023 | 0.83 | BRD4 (0.45) | PTPN11BRD4CDK8HTR6PDPK1 | |
| SCHEMBL2753498 | 0.83 | PDPK1 (0.49) | PTPN11BRD4CDK8HTR6PDPK1 | |
| SCHEMBL13746221 | 0.82 | BRD4 (0.44) | PTPN11BRD4HTR6AURKAPDPK1 | |
| SCHEMBL13745782 | 0.82 | PTPN11 (0.43) | PTPN11BRD4CDK8HTR6AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295433-A2 | JNK inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060270646-A1 | Jnk inhibitors | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270646-A1 | Jnk inhibitors | MAPKAPK2, MAPK1, MAPKAPK3 | PTPN11 1642/4885BRD4 1384/4885CDK8 362/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | PTPN11 1694/4885BRD4 1339/4885CDK8 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.